Tribute Pharmaceuticals: Co-Advisor

US$146,000,000

KES 7 Capital co-advised Tribute Pharmaceuticals in its merger with POZEN Inc. in a transformative transaction to create Aralez Pharmaceuticals (NASDAQ: ARLZ). With a world-class management and a broad portfolio of products, Aralez is poised to be a leading North American specialty pharmaceutical company. Prior to the closing of the merger with POZEN in Q1/2016, KES 7 Capital led equity and debt private placement financings for Tribute Pharmaceuticals throughout 2015 which enabled it to make key acquisitions of products and paved the way for its acquisition of privately held pharmaceutical company Medical Futures Inc. (MFI).

POZEN And Tribute Combine To Create Aralez Pharmaceuticals Inc.
Press release